This Thursday (6), the artificial intelligence tool Vita, developed in partnership with Hospital Sírio Libanês, gains another version. Now, the health chatbot will answer questions about prostate cancer.
Just access folha.com/prostata. No subscription required to use.
November 17th is World Day to Combat Prostate Cancer, a disease that kills 48 men a day in Brazil, despite the high chance of a cure.
“It is essential to raise awareness among the male population about the importance of taking care of their own health, and ‘Vita – Prostate Cancer’ offers reliable and quality information, validated by professionals from Sírio-Libanês”, says Diogo Assed Bastos, clinical oncologist at the hospital.
The user asks any questions they want related to prostate cancer, and the platform provides targeted results on symptoms, treatments and care.
The engine is based on natural language processing, AI capable of understanding human language to generate content. The data used is based only on hospital documents, guides and reports, as well as interviews from the Sheet carried out with the entity’s doctors.
Several answers are accompanied by videos with hospital doctors, recorded especially for Vita.
Interaction with the tool does not replace exams and consultations, nor does it carry out diagnoses or prescriptions for treatments and medications.
Bastos states that the risk of prostate cancer increases with age, so regular medical monitoring is necessary.
Although it is the second most common tumor in men, behind non-melanoma skin cancer, prostate cancer is still surrounded by prejudice, which keeps men away from doctors’ offices.
The first edition of Vita, published in Pink October 2024, answers questions about breast cancer and has more than 200 videos with oncologists, mastologists, radiotherapists, a pathologist and geriatrician, as well as nurses, a psychologist, a physiotherapist, nutritionists and an image consultant.
As with any AI product, there may be unexpected results.
This report is part of the Vita project, developed with support from Hospital Sírio-Libanês
